ARTICLE | Clinical News
VX-702 meets Phase II RA endpoint
March 9, 2006 2:22 AM UTC
Vertex (VRTX) said VX-702 met the primary endpoint of ACR20 response at week 12 in the Phase II VeRA trial to treat moderate to severe rheumatoid arthritis (RA). Preliminary results from the double-bl...